Gastro-oesophageal reflux disease (GORD).
Peptic ulcer disease caused by H. pylori.
Prophylaxis for NSAID-associated ulceration.
Adults and adolescents from the age of 12 years:
- Treatment of erosive reflux oesophagitis: 40 mg once daily in 4 weeks (if oesophagitis has not healed or persistent symptoms: 8 weeks).
- Long-term management of patients with healed oesophagitis to prevent relapse: 20 mg once daily.
- Symptomatic treatment of gastro-oesophageal reflux disease (GORD): 20 mg once daily in patients without oesophagitis. If symptom control has not been achieved after 4 weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily. In adults, an on-demand regimen taking 20 mg once daily, when needed, can be used. In NSAID treated patients at risk of developing gastric and duodenal ulcers, subsequent symptom control using an on-demand regimen is not recommended.
- In combination with an appropriate antibacterial therapeutic regimen for the eradication of pylori and prevention of relapse of peptic ulcers in patients with H. pylori [20 mg Esomeprazole + 1 g Amoxicillin + 500 mg Clarithromycin] twice daily in 7 days.
- Healing of gastric ulcers associated with NSAID therapy: 20 mg once daily in 4-8 weeks.
- Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily.
- Zollinger-Ellison syndrome: Initial 40 mg twice daily, then individually adjust. Doses between 80 to 160 mg daily (doses > 80 mg daily should be divided and given twice).
Children younger than 12 year of age: Should not use.
Patients with severe liver impairment: The maximum dose is 20 mg.
The capsules should be swallowed whole with some water. They should not be chewed or crushed.